The aim of the present study was to investigate the changes of miR155 expression in the serum of uremic patients before and after treatment and analyze the risk factors of efficacy. A total of 116 uremic patients admitted to the People's Hospital of Chengyang (Qingdao, China) were
enrolled in the study as the uremia group, and were treated by hemodialysis combined with hemoperfusion, and 127 healthy subjects who underwent health examination during the same period were selected as the normal group. Reverse transcription quantitative PCR was used to detect the serum miR155
levels of all the subjects in the two groups before treatment and those of uremia patients after treatment. The changes of clinically related indicators and inflammatory factors in uremic patients before and after treatment and their correlation with miR155 were investigated. The risk factors
affecting the efficacy of treatment were analyzed. Serum miR155 levels in the uremia group were higher than those in the normal group (P<0.001); the miR155 level in patients after treatment was significantly lower than that before treatment (P<0.001), and it was positively correlated
with efficacy (r=0.6873, P<0.05). The serum miR155 level in the invalid group was higher than that in the effective group, and the sensitivity and specificity of miR155 for predicting the efficacy before treatment were 64.71 and 87.88%, respectively. After treatment, the sensitivity and
specificity of miR155 for evaluating the efficacy were 76.47 and 88.89%, respectively. Clinically related indicators and inflammatory factor levels in uremic patients decreased significantly after treatment, and the expression levels before and after treatment were significantly correlated
with miR155. Clinically related indicators, inflammatory factors and miR155 were all risk factors affecting efficacy. The expression level of miR155 in serum was significantly upregulated. Findings of this study suggest that monitoring miR155 may reflect the efficacy and inflammatory state
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Nephrology, The People's Hospital of Chengyang, Qingdao, Shandong 266109, P.R. China
Intensive Care Unit, The People's Hospital of Chengyang, Qingdao, Shandong 266109, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites